Clamp AR - Search Results

1

Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.

Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell C, Salih Z, Woodward ER, Lalloo F, Shaw J, Desai S, Crosbie EJ, Edmondson RJ, Schlecht H, Wallace AJ, Jayson GC, Evans DGR. Morgan RD, et al. Among authors: clamp ar. J Clin Pathol. 2023 Oct;76(10):684-689. doi: 10.1136/jcp-2022-208369. Epub 2022 Jun 23. J Clin Pathol. 2023. PMID: 35738887

2

Weekly platinum chemotherapy for recurrent ovarian cancer.

Clamp A, Jayson GC. Clamp A, et al. Br J Cancer. 2002 Jan 7;86(1):2-4. doi: 10.1038/sj.bjc.6600062. Br J Cancer. 2002. PMID: 11857002 Free PMC article.

3

The clinical development of the bryostatins.

Clamp A, Jayson GC. Clamp A, et al. Anticancer Drugs. 2002 Aug;13(7):673-83. doi: 10.1097/00001813-200208000-00001. Anticancer Drugs. 2002. PMID: 12187323 Review.

4

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.

Clamp AR, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L, Jayson GC; Cancer Research UK Phase I/II Committee. Clamp AR, et al. Br J Cancer. 2003 Oct 6;89(7):1152-4. doi: 10.1038/sj.bjc.6601285. Br J Cancer. 2003. PMID: 14520436 Free PMC article. Clinical Trial.

5

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

Clamp A, Adams M, Atkinson R, Boven E, Calvert AH, Cervantes A, Ganesan T, Lotz J, Vasey P, Cheverton P, Jayson GC. Clamp A, et al. Gynecol Oncol. 2004 Oct;95(1):114-9. doi: 10.1016/j.ygyno.2004.06.047. Gynecol Oncol. 2004. PMID: 15385119 Clinical Trial.

6

Profiling heparan sulfate proteoglycans in ovarian carcinoma.

Clamp AR, Jayson GC. Clamp AR, et al. ScientificWorldJournal. 2005 Mar 20;5:230-3. doi: 10.1100/tsw.2005.31. ScientificWorldJournal. 2005. PMID: 15798883 Free PMC article. No abstract available.

7

Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.

Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, Gallagher JT, Jayson GC. Whitworth MK, et al. Among authors: clamp ar. Clin Cancer Res. 2005 Jun 15;11(12):4282-8. doi: 10.1158/1078-0432.CCR-04-1386. Clin Cancer Res. 2005. PMID: 15958608

8

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.

Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson GC. Hasan J, et al. Br J Cancer. 2005 Sep 19;93(6):647-51. doi: 10.1038/sj.bjc.6602752. Br J Cancer. 2005. PMID: 16222310 Free PMC article. Clinical Trial.

9

The clinical potential of antiangiogenic fragments of extracellular matrix proteins.

Clamp AR, Jayson GC. Clamp AR, et al. Br J Cancer. 2005 Oct 31;93(9):967-72. doi: 10.1038/sj.bjc.6602820. Br J Cancer. 2005. PMID: 16234821 Free PMC article. Review.

10

Heparin octasaccharides inhibit angiogenesis in vivo.

Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC. Hasan J, et al. Among authors: clamp ar. Clin Cancer Res. 2005 Nov 15;11(22):8172-9. doi: 10.1158/1078-0432.CCR-05-0452. Clin Cancer Res. 2005. PMID: 16299249

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page